ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Intercept Pharmaceuticals, Inc.

10 Hudson Yards
37th floor
New York, NY 10001
United States
646-747-1000
http://www.interceptpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees507

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark PruzanskiFounder, CEO, Pres & Director1.04M7.64M1968
Mr. Sandip S. KapadiaCFO, Treasurer & Principal Accounting Officer282.06kN/A1970
Dr. David Shapiro M.D., Ph.D.Chief Medical Officer688.88k295.76k1954
Ms. Lisa Bright B.Sc.Pres of International614.81kN/A1968
Mr. Jerome B. DursoChief Operating OfficerN/AN/A1968
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Corporate Governance

Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.